Telitacicept Phase 3 TELIGAN Trial Reports 104-Week Results in IgA Nephropathy
Start here
Final 104-week results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy were presented at the 2026 American Society of Nephrology annual meeting. The trial, which enrolled 318 patients in China, reported data on eGFR slope and proteinuria outcomes, the key measures of kidney function and disease activity in IgA nephropathy. Telitacicept is a dual-target biologic being developed as a treatment option for this kidney disease. The full 104-week dataset now presented represents the completed readout from the study; further details on regulatory filing plans and any subsequent trials have not yet been reported.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickPhase 3 TELIGAN Trial Reports 104-Week eGFR Slope and Proteinuria Results for Telitacicept in IgA Nephropathy
The TELIGAN trial presented final 104-week results for telitacicept in IgA nephropathy at the 2026 American Society of Nephrology (ASN) annual meeting. The study enrolled 318 patients in China.
Heat trend for this story
Heat now 7·Peak in the comparable set 8 (Oct 23 10:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.